Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG).

Abstract

Cytomegalovirus (CMV) infection is a frequent cause of serious illness in heart transplant patients and may cause life-threatening pneumonia, with a reported mortality of greater than 50%. We investigated the clinical efficacy of a new antiviral agent, 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG) in the treatment of CMV pneumonia in heart transplant patients. Four of these patients with biopsy-proved CMV pneumonia were treated with DHPG, with resolution of pneumonia and no relapse at a mean follow-up period of 21 weeks. DHPG may be useful in the treatment of CMV pneumonia in heart transplant patients.

• Authors: F S Watson, J B O'Connell, I J Amber, D G Renlund, D Classen, J M Johnston, C B Smith, M R Bristow
• Journal: The Journal of heart transplantation (J Heart Transplant) 1988 Mar-Apr Vol. 7 Issue 2 Pg. 102-5 ISSN: 0887-2570 [Print] United States
• PMID: 2835468 (Publication Type: Journal Article)

Chemical References

• Immunosuppressive Agents
• Ganciclovir
• Acyclovir

Topics

• Acyclovir (adverse effects, analogs & derivatives, therapeutic use)
• Adult
• Cytomegalovirus Infections (drug therapy, etiology)
• Ganciclovir
• Heart Transplantation
• Humans
• Immunosuppressive Agents (adverse effects)
• Leukopenia (chemically induced)
• Male
• Middle Aged
• Nausea (chemically induced)
• Pneumonia, Viral (drug therapy, etiology)